u/purity_pedant

Strongly agree. Step therapy is predictable if you have the criteria.

escrow for group buys is standard, use it

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

Disagree. What you are describing is consistent with long term, not with what you concluded.

oral non-peptide agonist is orforglipron, no food restrictions

PDF metadata is checkable in fifteen seconds

Disagree on that part. 97.9% and 97.6% on the same vial is normal.

Removed a chain here. The rule is one line long and it is not negotiable.

This is correct. Gas fees are real costs.

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.

The plateau is real and boring. 59 weeks at the same weight, then movement again. Patience was the intervention.

network selection matters, wrong chain is the expensive typo

Mechanistically the bit that matters is area percent. It explains most of the early profile and a decent chunk of the outcome.

This is correct. ATTAIN data is phase 15.

Regain on a taper is expected. 12% back over 20 weeks, which matches the discontinuation data. Planned for it.

Did you check confirmation speed on that chain?

stablecoin is chargeback, never volatile coins

Tried the lowest-effective approach. 2.5mg worked for 9 weeks, then cravings returned. 5mg was the actual floor.

USDC exists on 24 networks, vendor credits are network-specific

Regain on a taper is expected. 13% back over 9 weeks, which matches the discontinuation data. Planned for it.

do not suggest misrepresenting a diagnosis, that is fraud